|Titre :||Quantitative criteria to screen for cannabis use disorder (2018)|
|Auteurs :||C. CASAJUANA ; H. LOPEZ-PELAYO ; L. MIQUEL ; M. M. BALCELLS-OLIVERO ; J. COLOM ; A. GUAL|
|Type de document :||Article : Périodique|
|Dans :||European Addiction Research (Vol.24, n°3, July 2018)|
|Article en page(s) :||109-117|
|Discipline :||EPI (Epidémiologie / Epidemiology)|
Thésaurus TOXIBASECAST ; CANNABIS ; DEPISTAGE ; MESURES QUANTITATIVES ; PROFIL SOCIO-DEMOGRAPHIQUE ; FACTEUR DE RISQUE ; TEST
INTRODUCTION: The Standard Joint Unit (1 SJU = 7 mg of 9-Tetrahydrocannabinol) simplifies the exploration of risky patterns of cannabis use. This study proposes a preliminary quantitative cutoff criterion to screen for cannabis use disorder (CUD).
METHODOLOGY: Socio-demographical data and information on cannabis quantities, frequency of use, and risk for CUD (measured with the Cannabis Abuse Screening Test (CAST) of cannabis users recruited in Barcelona (from February 2015 to June 2016) were collected. CAST scores were categorized into low, moderate, and high risk for CUD, based on the SJU consumed and frequency. Receiver operating characteristic (ROC) analysis related daily SJU with CUD.
RESULTS: Participants (n = 473) were on average 29 years old (SD = 10), men (77.1%), and single (74.6%). With an average of 4 joints per smoking day, 82.5% consumed cannabis almost every day. Risk for CUD (9.40% low, 23.72% moderate, 66.88% high) increased significantly with more frequency and quantities consumed. The ROC analyses suggest 1.2 SJU per day as a cutoff criterion to screen for at least moderate risk for CUD (sensitivity 69.4%, specificity 63.6%).
CONCLUSION: Frequency and quantity should be considered when exploring cannabis risks. A 1 SJU per day is proposed as a preliminary quantitative-based criterion to screen users with at least a moderate risk for CUD.
|Domaine :||Drogues illicites / Illicit drugs|
|Refs biblio. :||28|
|Affiliation :||Department of Psychiatry, Grup de Recerca en Adiccions Clinic (GRAC), Addictions Unit, Clinical Institute of Neuroscience, Hospital Clinic, Universitat de Barcelona, Red de Trastornos Adictivos (RTA), Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain|